undamentalytics Newsletter

Dawes Karen A: insider trades

Director at Repligen Corp. 2 open-market purchases and 21 sales not made under a pre-set plan, reported from June 15, 2011 to December 18, 2025.

Would copying Dawes Karen A’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved +1.6% against the index over 12 months on average (a negative figure means selling was the right call); 70% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Dawes Karen A: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 21 +2.7% −3.1% 52% 9 −0.48 0.64 No reliable evidence
Sales, 12 months after the report 20 +1.6% −9.9% 70% 8 −0.06 0.95 No reliable evidence
Sales, 12 months after the trade 20 +1.8% −11.6% 70% 8 0.08 0.94 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Repligen Corp RGEN —221June 15, 2011December 18, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 18, 2025December 17, 2025 RGEN Sale $44,275 −24.6%not yetnot yet
February 28, 2024February 27, 2024 RGEN Sale $193,350 −26.8%−35.2%−36.1%
August 30, 2023August 29, 2023 RGEN Sale $145,673 −11.3%−42.8%−38.4%
September 9, 2022September 9, 2022 RGEN Sale $176,057 −25.8%−42.0%−43.9%
May 26, 2022May 25, 2022 RGEN Sale $2,214,819 +32.6%−3.6%+3.4%
November 12, 2021November 10, 2021 RGEN Sale $1,262,355 −24.2%−5.9%−14.7%
November 4, 2021November 2, 2021 RGEN Sale $729,467 −20.3%−17.8%−25.7%
September 15, 2021September 14, 2021 RGEN Sale $80,628 −18.3%−14.0%−13.0%
September 2, 2021September 1, 2021 RGEN Sale $982,058 −10.5%−14.7%−14.2%
August 19, 2021August 17, 2021 RGEN Sale $4,818,219 +0.3%−8.6%−0.8%
July 22, 2021July 20, 2021 RGEN Sale $926,605 +25.5%+2.7%−5.8%
July 15, 2021July 13, 2021 RGEN Sale $307,390 +31.3%−9.7%−5.7%
May 13, 2021May 11, 2021 RGEN Sale $50,402 +42.6%−10.2%−13.4%
June 22, 2020June 18, 2020 RGEN Sale $2,154,851 +14.2%+23.9%+37.4%
May 21, 2020May 20, 2020 RGEN Sale $72,093 −6.7%−17.5%−11.7%
May 19, 2020May 18, 2020 RGEN Sale $220,448 −7.8%−11.7%−15.1%
April 22, 2020April 20, 2020 RGEN Sale $1,275,717 +4.6%+41.2%+54.8%
February 24, 2020February 21, 2020 RGEN Sale $394,793 +60.7%+126.1%+96.6%
June 19, 2019June 17, 2019 RGEN Sale $100,168 −3.1%+32.1%+40.3%
May 15, 2018May 11, 2018 RGEN Sale $836,000 +12.7%+52.8%+53.7%
March 22, 2017March 21, 2017 RGEN Sale $86,017 +11.2%−13.2%−11.6%
August 15, 2011August 12, 2011 RGEN Purchase $34,900 not yetnot yetnot yet
June 15, 2011June 14, 2011 RGEN Purchase $16,086 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Dawes Karen A traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.